Business Context and Reporting Period
Daré Bioscience, Inc., a Delaware corporation and emerging growth company, filed this Form 8-K on April 9, 2019. The report details the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 4,575,000 shares of common stock.
- Offering Price: $1.10 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 686,250 additional shares (15% of the offering).
- Expected Net Proceeds: Approximately $4.4 million (assuming no exercise of the over-allotment option and after deducting discounts, commissions, and expenses).
- Use of Proceeds: Working capital, general corporate purposes, advancing the product candidate portfolio, and general and administrative expenses.
- Expected Closing Date: April 11, 2019.
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a current report regarding a capital raise rather than a periodic financial statement.
Material Changes and Covenants
As a result of the underwriting agreement, Daré Bioscience agreed to a 60-day lock-up period following the closing of the offering. During this period, the company is restricted from issuing, agreeing to issue, or announcing the issuance of any shares of common stock or securities convertible into or exercisable for common stock, subject to certain exceptions.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance its product candidate portfolio. The offering is subject to customary closing conditions. The filing notes that the underwriting agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the final closing of the offering and whether the underwriters exercised the 686,250 share over-allotment option.
- Confirm the actual net proceeds received after all transaction expenses.
- Review the final prospectus supplement filed under Rule 424(b) for updated risk factors and use of proceeds details.
- Monitor the company's cash runway and burn rate in light of the $4.4 million capital raise.
- Check for any subsequent filings regarding the 60-day lock-up expiration and potential future equity issuances.